Display Settings:

Format

Send to:

Choose Destination
    Postgrad Med J. 2007 Jun;83(980):e1.

    Sulfasalazine-induced immune thrombocytopenia.

    Source

    Rheumatology Unit, Department of Clinical Medicine and Immunological Sciences, University of Siena, Italy.

    Abstract

    Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.

    PMID:
    17551063
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2600053
    Free PMC Article

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk